Literature DB >> 21444695

Prospective, open-label investigation of the pharmacokinetics of daptomycin during cardiopulmonary bypass surgery.

Megan H Nguyen1, Samantha J Eells, Jennifer Tan, Corinne T Sheth, Bassam Omari, Margarita Flores, Jeffrey Wang, Loren G Miller.   

Abstract

As methicillin-resistant Staphylococcus aureus (MRSA) becomes more prevalent, vancomycin is becoming increasingly used as a prophylaxis against surgical-site infections for cardiothoracic surgeries. However, vancomycin administration can be challenging, and the pharmacokinetics of alternative antibiotics in this setting are poorly understood. The primary objective of this investigation was to describe the pharmacokinetics of daptomycin in patients undergoing coronary artery bypass graft surgery. We enrolled 15 patients undergoing coronary artery bypass surgery requiring cardiopulmonary bypass. Each subject was administered a single open-label dose of daptomycin (8 mg/kg of body weight) for surgical prophylaxis. Fourteen daptomycin plasma samples were collected. Safety outcomes between subjects who received daptomycin and 15 control subjects who received the standard-of-care antibiotic were compared. The mean maximal concentration of daptomycin (C(max)) was 84.4 ± 27.1 μg/ml; the mean daptomycin concentration during the cardiopulmonary bypass procedure was 33.2 ± 11.4 μg/ml and was 30.9 ± 12.7 μg/ml at sternum closure. Mean daptomycin concentrations at 12, 18, 24, and 48 h were 22.7 ± 9.7, 16.2 ± 8.2, 12.0 ± 4.7, and 3.5 ± 2.3 μg/ml, respectively. Mean daptomycin concentrations were consistently above the MIC at which 90% of the tested isolates are inhibited (MIC₉₀) for S. aureus and S. epidermidis during the cardiopulmonary bypass procedure. Daptomycin was not associated with surgical-site infections or differences in adverse events compared to findings for control subjects. We found that a single dose of daptomycin at 8 mg/kg was well tolerated and achieved adequate plasma concentrations against common pathogens associated with surgical-site infections after cardiothoracic surgery. Daptomycin may be considered an alternative surgical prophylaxis antibiotic for patients undergoing cardiothoracic bypass surgery who are unable to receive vancomycin.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21444695      PMCID: PMC3101392          DOI: 10.1128/AAC.01404-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  46 in total

Review 1.  The pharmacokinetics of anesthetic drugs and adjuvants during cardiopulmonary bypass.

Authors:  B Mets
Journal:  Acta Anaesthesiol Scand       Date:  2000-03       Impact factor: 2.105

2.  Serum levels of prophylactic cefazolin during cardiopulmonary bypass surgery.

Authors:  Erika K Fellinger; Bruce J Leavitt; James C Hebert
Journal:  Ann Thorac Surg       Date:  2002-10       Impact factor: 4.330

3.  Impact of methicillin-resistant Staphylococcus aureus prevalence among S. aureus isolates on surgical site infection risk after coronary artery bypass surgery.

Authors:  Loren G Miller; James A McKinnell; Michael E Vollmer; Brad Spellberg
Journal:  Infect Control Hosp Epidemiol       Date:  2011-04       Impact factor: 3.254

4.  Sternal surgical-site infection following coronary artery bypass graft: prevalence, microbiology, and complications during a 42-month period.

Authors:  Mamta Sharma; Dorine Berriel-Cass; Joseph Baran
Journal:  Infect Control Hosp Epidemiol       Date:  2004-06       Impact factor: 3.254

5.  Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model.

Authors:  Prachi K Dandekar; Pamela R Tessier; Peter Williams; Charlie H Nightingale; David P Nicolau
Journal:  J Antimicrob Chemother       Date:  2003-08-13       Impact factor: 5.790

6.  Vancomycin blood levels during cardiac bypass surgery.

Authors:  T W Austin; J Leake; J C Coles; M M Goldbach
Journal:  Can J Surg       Date:  1981-07       Impact factor: 2.089

7.  Update of the in vitro activity of daptomycin tested against 6710 Gram-positive cocci isolated in North America (2006).

Authors:  Mariana Castanheira; Ronald N Jones; Hélio S Sader
Journal:  Diagn Microbiol Infect Dis       Date:  2008-03-07       Impact factor: 2.803

8.  Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers.

Authors:  J R Woodworth; E H Nyhart; G L Brier; J D Wolny; H R Black
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

9.  Effect of cardiopulmonary bypass on vancomycin and netilmicin disposition.

Authors:  K J Klamerus; K A Rodvold; N A Silverman; S Levitsky
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

10.  Enhanced identification of postoperative infections among inpatients.

Authors:  Deborah S Yokoe; Gary A Noskin; Susan M Cunnigham; Gianna Zuccotti; Theresa Plaskett; Victoria J Fraser; Margaret A Olsen; Jerome I Tokars; Steven Solomon; Trish M Perl; Sara E Cosgrove; Richard S Tilson; Maurice Greenbaum; David C Hooper; Kenneth E Sands; John Tully; Loreen a Herwaldt; Daniel J Diekema; Edward S Wong; Michael Climo; Richard Platt
Journal:  Emerg Infect Dis       Date:  2004-11       Impact factor: 6.883

View more
  2 in total

Review 1.  Daptomycin Pharmacokinetics and Pharmacodynamics in Septic and Critically Ill Patients.

Authors:  Antonio D'Avolio; Debora Pensi; Lorena Baietto; Giovanni Pacini; Giovanni Di Perri; Francesco Giuseppe De Rosa
Journal:  Drugs       Date:  2016-08       Impact factor: 9.546

2.  Serum level of prophylactic antibiotics in cardiac surgery and its implication on surgical site infection (SSI).

Authors:  Turki B Albacker; Hussain Alqattan; Saeed A Alqahtani; Sultan Alamro; Norah Alsuwaidan; Alhanouf Alaloola; Ahmed Eldemerdash; Bakir Bakir
Journal:  Am J Cardiovasc Dis       Date:  2022-08-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.